News | Reporting Season

Why relentless innovation is Pro Medicus’ biggest opportunity and risk

There are only two states in software according to Pro Medicus CEO Dr Sam Hupert: "quick or dead".

Chris Conway

Managing Editor

16 February 2024

∙This article is more than 12 months old and may be outdated

∙1 min read

Mentioned

HIGHLIGHTS

Pro Medicus (ASX: PME) has garnered significant market attention in recent years, emerging as a growth stock standout
The company's share price has soared from just above $4 in 2017 to a high exceeding $111, despite a recent sharp selloff, reflecting its remarkable growth trajectory alongside record results
Co-founder and CEO Dr. Sam Hupert, far from stepping back, remains deeply engaged in the industry, declaring this as the prime time to be involved
He sees artificial intelligence as a complementary force in healthcare imaging, capable of elevating standards further
In an interview, Hupert discusses recent major contract wins and the future pipeline, as well as the company's approach to collaborating with thought leaders to expand opportunities

ABOUT THE AUTHOR

Chris Conway

Managing Editor

Chris is the Managing Editor at Livewire Markets and Market Index. His passion is equity research, portfolio construction, and investment education. He is also very keen on the powerful processes that can help all investors identify great opportunities and outperform the market, and wants to bring them to life and share them with you.

Printed

05/06/2026